

Undertaking by the Principal Investigator/Co-PI/HoD towards carrying out primary screening of the samples against identified disease area at CSIR-CDRI

(to be signed by the Principal Investigator/Co-PI/HoD individually and endorsed by the competent authority)

I,

Mr./Ms./Mrs./Dr./Prof. _____

working as _____ at _____

request **CSIR-Central Drug Research Institute, Lucknow, India** to carry out primary

screening of the sample(s) bearing the code No(s) _____



against (define activity) _____ I.

I wish to submit the samples for the purposes of conducting primary screening pertaining to the project (if there is any) entitled _____

under the framework/scheme of _____ granted by _____

at **CSIR-Central Drug Research Institute, Lucknow**.

It is to undertake that I shall:

- (1) abide by the scope of the work that is restricted to carry out the primary screening of the sample(s) derived from the synthetic/semi-synthetic/plant based/natural products and aware of the fact that any work involving radioactive materials/isotopes is outside its purview.
- (2) at our cost provide the sample(s) to CSIR-CDRI as per **Annexure I**.

- (3) maintain the repository of the sample(s) sent to CSIR-CDRI for future reference and provide the same, as and when required, for repeat experiments/ analysis and/or secondary screening.
- (4) provide the required information which is necessary for conducting the requested screening.
- (5) not file any application for protection of any IP generated directly or indirectly through any third party, whosoever, without prior written approval from Director, CSIR-CDRI. In case any sample(s) is developed and/or being developed by our organization without the approval of Director CSIR-CDRI, then CSIR-CDRI shall also be free to develop the same without any liability, whatsoever, to our organization.
- (6) not give/donate/distribute/exhibit any results in question without the written permission from the competent authority from CSIR-CDRI.
- (7) vest the decision relating to the communicating authorship solely on the scientist involved in sample(s) screening and not publish any data/information pertaining to the project without any prior written permission from CSIR-CDRI.
- (8) acknowledge appropriately, in case the CSIR-CDRI scientist is not interested towards authorship, the scientific and technical contributions whatsoever made by whosoever pertaining to this work, in consultation with the same.
- (9) agree, in case results of primary screening are encouraging, the secondary screening would be carried out at CSIR-CDRI.
- (10) agree that the intellectual property generated shall be dealt by a separate agreement for protection and further technology development whatsoever under the scope of the said screening between the CSIR-CDRI and the organization that I represent.
- (11) approach any funding agency under a joint proposal with CSIR-CDRI for further development of any sample(s).
- (12) maintain the confidentiality and non-disclosure of the information on the results of the screening and agree that the right to transfer of the Know-how generated, to any third party shall be decided mutually.
- (13) ensure that, any person from our side visiting CSIR-CDRI shall acquaint with the laboratory procedures and related health risks/hazards/safety aspects and shall have prior adequate insurance coverage without any financial liability on CSIR-CDRI and further, do not make CSIR-CDRI liable on the event of any accident/mishap takes place due to any reason whatsoever during the tenure of stay of that person in CSIR-CDRI.

(Signature of the Principal Investigator)

Name & Address:

Date: _____

Place: _____

Endorsement by the competent authority of the institution from where the Principal Investigator/Co-PI/HoD's request is forwarded.

I am forwarding the request of Mr./Ms./ Prof./Dr.

for carrying out primary screening of sample(s) against the _____ studies to be conducted at CSIR-Central Drug Research Institute, Lucknow.

The institution agrees to administer the points enlisted and agreed upon by the candidate.

It is certified that the Principal Investigator/Co-PI/HoD,

will/is likely to continue with the Institution till the completion of the proposed study.

(Signature of competent authority of the institution)
Name & Address:

Office Seal:

CSIR - Central Drug Research Institute, Lucknow

Date: _____

Place: _____

ANNEXURE I

Guidelines for testing of sample

(Please read carefully the provisions of undertaking before sending any samples to CSIR-CDRI)

(Studies shall be initiated at the earliest depending upon the date of the receipt of the adequate quantity of the samples and supply of the required information)

The request for proposed studies is to be made by the Principal Investigator/Co-PI/HoD or any authorized person for and on behalf of the organization to any one of the contact persons of CSIR-CDRI (<http://www.cdriindia.org/biologicalscr.htm>).

Students / research scholars are advised to contact CSIR-CDRI through proper channel as no sample will be accepted directly.

The undertaking duly signed by the authorized person for and on behalf of the organization shall be sent to CSIR-CDRI for the signature of the competent authority of CSIR-CDRI along with the samples in acceptable form (solid or neat liquid), along with the information as mentioned below:

| S.No | Item/parameter | Description |
|------|--------------------|---|
| 1 | Compound Code No. | Samples with proper code nos. are considered |
| 2 | Number of samples | Upto 25 samples may be screened |
| 3 | Quantity of sample | Two Eppendorf vials (1 for screening + 1 for repository) As per requirements given under specific disease areas section of http://www.cdriindia.org/biologicalscr.htm page. |
| | | Neat Liquid: As above in sealed containers. |
| 4 | Sample shipment | The sample(s) should be sent in Eppendorf vial (1.5 ml capacity) and shall carry proper Code Nos. and labels. |
| 5 | Nature of compound | Non-hazardous |

A: In case of Synthetic Compound(s):

| S.No | Item/parameter | Description |
|------|--------------------|--|
| 1 | Chemical name | In accordance with IUPAC nomenclature |
| 2 | Structural formula | Complete along with purity analysis details |
| 3 | Purity | >90% (supported by HPLC and spectral data) |
| 4 | Others | Melting/boiling point, molecular formula, molecular weight, solubility |

B: In case of Plant extract(s):

| S.No | Item/parameter | Description |
|------|--------------------|--|
| 1 | Plant Nomenclature | Name of the plant along with authentic herbarium specimen, synonyms, family, etc., collection details such as place and period of collection |
| 2 | Plant Part | Plant part studied along with purity analysis details |
| 3 | Solvent | Solvent used for extraction |